Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
- Cancer
- Concussions
- CRISPR
- Drug Pricing
- End of Life
- Health Disparities
- Immigration
- Opioids
- Trump
- Women’s Health
- Zika
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Drug Prices

Pharmalot

Pharmalittle: GSK looks to sell antibiotics unit; China wins big price cuts on drugs

By Ed Silverman

The Pharmalot View

The art of the deal? Why a money-back guarantee for drugs is a bad idea

By Ed Silverman

advertisement

Biotech

Trump’s FDA may be lowering the standards for drug approvals. What’s the fallout?

By Adam Feuerstein

advertisement

Pharmalot

This bill would reinstate a controversial drug discount for some hospitals

By Ed Silverman

Pharmalot

A Senate bill would require drug makers to justify price hikes

By Ed Silverman

Politics

Senate set to hear pitch on three ideas to bring down drug prices

By Erin Mershon

Pharmalot

Pfizer has raised prices on nearly 100 drugs by an average of 20 percent

By Ed Silverman

advertisement

Pharma

Medicare patients don’t share in drug discounts given insurers and PBMs

By Sarah Jane Tribble — Kaiser Health News

advertisement

Pharmalot

Bipartisan bill will be reintroduced to force pharma to justify price hikes

By Ed Silverman

Pharmalot

Lower FDA approval standards could have cost billions for a failed Alzheimer’s drug

By Ed Silverman

Pharmalot

Louisiana explores whether to override patents to fight hepatitis C drug costs

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Feds raid Perrigo in search of pricing information

By Ed Silverman

Pharmalot

Gilead loses a patent battle over Sovaldi in Brazil

By Ed Silverman

Pharmalot

Winners and losers: Who had a good week – and who didn’t

By Ed Silverman

Politics

PhRMA report pins consumers’ pain from high drug prices on health plans

By Dylan Scott

Pharmalot

Not just Colombia: Novartis has charged more for some drugs in Mexico, too

By Ed Silverman

Pharmalot

A new Senate bill would require PBMs to disclose some rebate info

By Ed Silverman

Pharmalot

Some states consider making it easier to dispense EpiPen alternatives

By Ed Silverman

Pharmalot

Still more lawmakers are probing Marathon over its DMD drug pricing

By Ed Silverman

Pharmalot

To import or not to import? Lawmakers push another bill to combat high drug prices

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Johnson & Johnson discloses drug prices to deflect criticism

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Some pharma execs exude confidence over US pricing

By Ed Silverman

Pharmalot

Chile’s congress votes to pursue compulsory licenses for medicines

By Ed Silverman

Pharmalot

An EpiPen rival will return, but with a questionable strategy

By Ed Silverman

Pharmalot

Alexion battles Canada over forfeiting sales for an ‘excessively’ priced drug

By Ed Silverman

Pharma

Pfizer chief: Hatred of pharma is ‘a problem of perception’

By Damian Garde

Pharmalot

Few Americans believe pharma places patients over profits: poll

By Ed Silverman

Biotech

Biopharma expects a lot of M&A this year

By Meghana Keshavan

Pharmalot

In closely watched case, Colombia cuts the price of a Novartis cancer drug by 44 percent

By Ed Silverman

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT